MORGANTOWN, W. Va., May 1, 2012 (GLOBE NEWSWIRE) -- Protea Biosciences Group, Inc., a leading developer of technologies and services for biomolecular analysis, today announced the opening of its new 10,000 sq. ft. laboratory services facility in Morgantown, West Virginia. The new laboratory features Protea's recently-acquired Synapt(R) G2-S high definition mass spectrometer from Waters Corporation (NYSE:WAT), which will interface with Protea's proprietary LAESI DP-1000 Direct Ionization System to provide state-of-the-art biomolecular profiling services.
Alessandro Baldi, Protea's Vice President and General Manager, stated, "The combination of the Waters' Synapt G-2 high definition mass spectrometer and our LAESI DP-1000 provides our customers an unparalleled level of discovery opportunities. We are offering pharmaceutical companies the ability to reach new frontiers in medicine. With this new lab and our cutting edge LAESI technology, we have built the capacity to support scientists focused on a more accurate understanding of the biological mechanisms and molecules involved in disease. The addition of LAESI-based services gives us the opportunity to perform direct ionization and 2D-3D mapping of biological samples at ambient temperature and pressure, without the need for time consuming sample preparation. Using LAESI at our new facility will increase our overall biomolecular profiling throughput and empower researchers with data that was previously unimaginable."
Protea's LAESI (Laser Ablation Electrospray) technology allows for two and three dimensional distribution profiles of molecules in biological samples for unambiguous drug/target interaction studies, as well as the study of bio-dynamics directly from living cell cultures. The Synapt G2-S from Waters combines ion mobility separation with high resolution mass spectrometry for identification of unknown compounds and molecular quantitation in complex biological samples.
Protea's bioanalytical services laboratory provides biopharmaceutical companies the expertise to examine a wide array of biomolecules using GLP validated methodologies as well as innovative methods such as LAESI to accelerate the discovery process, reduce time to market, and provide more accurate and reliable information throughout the drug development process.
Protea is a leader in the field of bioanalytics – the identification and characterization of proteins, metabolites, and other biomolecules, which are the products of all living cells and life forms – technology that is foundational for all pharmaceutical and life science research.
The Protea Biosciences, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=13098
Forward-Looking Statements
This press release may contain certain statements relating to future results, which are forward-looking statements. These statements are not historical facts, but instead represent only the Company's belief regarding future events, many of which, by their nature, are inherently uncertain and outside of the Company's control. It is possible that the Company's actual results and financial condition may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements. Further, information concerning the Company and its business, including factors that potentially could materially affect the Company's financial results, are contained in the Company's filings with the Securities and Exchange Commission. All forward-looking statements included in this press release are made only as of the date of this press release, and we do not undertake any obligation to publicly update or correct any forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware.
Protea website: www.proteabio.com
Protea Bioanalytical Services: https://proteabio.com/services
LAESI 2D- 3D Molecular profiling: https://proteabio.com/LAESI/LAESI-Based+Services
Waters and Synapt are registered trademarks of Waters Corporation